Best Life Sciences Companies in Nijmegen, Netherlands
The 44 best Life Sciences companies in Nijmegen, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Xenikos.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Nijmegen
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Xenikos Developer of toxin-loaded antibodies for T-cell mediated diseases | $82M | 46 mo ago | 17 | — | — | 6 patents Targeted immunotoxin therapeutics for cancer treatment | — |
| 2 | Tagworks Pharmaceuticals Developer of antibody-drug-conjugates for cancer treatment | $65M | 38 mo ago | 13 | Zach Taylor Co-Founder | WordPressMySQLPHP+22 | 144 patents Bioorthogonal click chemistry reagents for targeted drug/protein delivery and release | — |
| 3 | TIBEAY Biosciences Clinical-stage biopharmaceutical company focused on developing innovative therapies for acute neurological… | $41M | 4 mo ago | — | Klaas Boer Co-Founder | — | — | — |
| 4 | ScreenPoint Developer of artificial intelligence software for analyzing breast imaging mammograms | $33M | 4 mo ago | 58 | Michael Brady Co-Founder & Chairman | WordPressMySQLPHP+21 | — | — |
| 5 | InteRNA Technologies Discovering and developing microRNA (miRNA)-based therapeutics for oncology | $33M | 66 mo ago | 13 | — | — | 20 patents miRNA-based cancer diagnostics and therapeutics targeting EMT and B‑RAF pathways | — |
| 6 | Enzyre Developer of smart diagnostics devices for blood coagulation analysis | $12M | 45 mo ago | 20 | — | WordPressMySQLPHP+12 | 23 patents Patents concentrated in transport & manufacturing processes | — |
| 7 | Alveron Pharma Developer of drugs to treat haemorrhagic stroke or intracranial haemorrhage | $12M | 58 mo ago | 3 | — | — | 8 patents Cyclodextrin-based procoagulant formulations for hemostatic drug delivery | — |
| 8 | GATT Technologies BV Polymer-based General Adhesive Tissue Tape | $11M | 62 mo ago | 22 | Johan Bender Founder | — | — | — |
| 9 | CardiacBooster Provider of percutaneous left ventricular assist devices | $11M | 12 mo ago | 18 | — | WordPressMySQLPHP+16 | 42 patents Mechanical circulatory support devices—axial-flow and high-frequency cardiac assist pumps. | — |
| 10 | Mellon Medical A suturing device with only one hand needed to operate the device | $7M | 106 mo ago | 6 | — | — | 53 patents Innovative needle‑suture combos and coupling mechanisms for surgical suturing devices | — |
| 11 | Khondrion Small molecule therapeutics for mitochondrial diseases | $4M | 21 mo ago | — | Jan Smeitink Founder & CEO | Webflowcore-jsjQuery+11 | 92 patents Small-molecule therapeutics for mitochondrial disease and MPGES‑1‑mediated neuroinflammation | — |
| 12 | QurieGen AI-powered drug discovery platform for cancer treatment | $2M | 16 mo ago | — | Kinga Matula Founder & CEO | — | — | 1 partnership |
| 13 | MindAffect Manufacturer and developer of industrial robots | $2M | 27 mo ago | 10 | Ivo Box Co-Founder & CEO | WixSentryBootstrap+15 | 10 patents Assessing sensory capabilities using bioelectrical electrode sensing for health diagnostics | — |
| 14 | ATRO Medical Developer of a polymer-based meniscus implant | $2M | 6 mo ago | 9 | Tony Tienen CEO & CMO | PrismicCart FunctionalityNode.js+17 | 23 patents Flexible meniscus prostheses for knee and stifle joint replacement and stabilization | — |
| 15 | Aiosyn AI-based disease diagnosis tool for providers | $2M | 11 mo ago | 15 | Jeroen der Laak Co-Founder | WordPressMySQLRedis+28 | — | — |
| 16 | Bio-Prodict Developer of a bioinformatics computational platform for the analysis of biological data | $2M | 62 mo ago | — | Henk-Jan Joosten CEO & Owner | — | — | — |
| 17 | TROPIQ Health Sciences Barcoded live insect screening technology | $464K | 54 mo ago | 15 | Koen Dechering Cofounder and VP of business development | — | 16 patents Patents concentrated in health & consumer products | — |
| 18 | NovioSense In the eye connected continuous glucose monitor for diabetes | $309K | 118 mo ago | 3 | — | — | 17 patents Implantable biosensor devices and biocompatible coating technologies for medical implants | — |
Top 12 Life Sciences companies in Nijmegen
#1
Series C · Nijmegen, Gelderland · founded 2014 · 58 employees$33Mraised▾
Developer of artificial intelligence software for analyzing breast imaging mammograms. This technology integrates with existing medical imaging hardware to assist radiologists in detecting cancer. The software provides automated analysis of breast density and compares current images against previous examinations to identify potential abnormalities. It functions across various imaging systems to support clinical workflows in diagnostic environments.
- Apr 2026Series C$14M
- Apr 2026Grant (prize money)$2M
- Jul 2021Series C$28M
- May 2018Series B$5M
#2
Series C · Nijmegen, Gelderland · founded 2025$41.2Mraised▾
Clinical-stage biopharmaceutical company focused on developing innovative therapies for acute neurological conditions. The company focuses on developing therapies for acute neurological conditions. Its lead compound, Ronopterin, a selective iNOS inhibitor, for severe traumatic brain injury. It aims to reduce secondary brain injury, a condition with no approved pharmacological treatment.
- Apr 2026Series C$41.2M
#3
Series A · Nijmegen, Gelderland · founded 2016 · 9 employees$2.1Mraised▾
Developer of a polymer-based meniscus implant. The company has developed Trammpolin, a synthetic, non-resorbable anatomically shaped polymer-based meniscus implant for restoring the protective function of the meniscus by acting as a joint spacer. It reduces pain and restores mobility.
- Feb 2026Series A$3.5M
- Jan 2022Grant (prize money)$2.7M
- Dec 2021Series A$2.1M
- 2018Series A—
#4
Funding Raised · Nijmegen, Gelderland · founded 2018 · 18 employees$10.8Mraised▾
CardiacBooster provides percutaneous left ventricular assist devices. The company's devices are used to support the cardiac function of hemodynamically unstable patients. The device focus on ventricular support, cardiogenic shock, and high-risk PCI.
- Aug 2025Grant (prize money)$10.8M
- Dec 2019Grant (prize money)—
- Nov 2018Conventional Debt—
#5
Series A · Nijmegen, Gelderland · founded 2021 · 15 employees$2.1Mraised▾
AI-based disease diagnosis tool for providers. The company has developed software that assists with clinical disease diagnosis. It has features for breast and prostate cancer diagnostics, computational pathology, disease diagnosis, and more.
- Sep 2025Series A$2.8M
- Dec 2022Seed$2.1M
- Feb 2022Seed—
#6
Seed · Nijmegen, Gelderland · founded 2010$4Mraised▾
Khondrion focused on developing small molecule therapeutics for mitochondrial diseases. Its lead candidate KH176 is an orally bio-available small molecule being developed for the treatment of MELAS syndrome and other mitochondrial respiratory chain/OXPHOS diseases (Phase 1). KH176 is a member of a class of drugs essential for the control of oxidative and redox pathologies. Both European Commission and US- FDA has granted KH176 an orphan drug designation for all inherited mitochondrial respiratory chain disorders. The company also has a strategic partnership with the Nijmegen Centre for Mitochondrial Disorders of the Radboud University Medical Centre, Nijmegen. The company is supported by the Dutch Foundations Energy4All, Join4Energy, Ride4Kids, Road4Energy, Tim Foundation, Zeldzame Ziekten Fonds, the Prinses Beatrix Fonds, and National (NWO, ALW, ZonMW) and European Governments (Marie-Curie ITN, Eurostars).
- Nov 2024Seed—
- Nov 2022Grant (prize money)$270.8K
- Sep 2021Grant (prize money)$58.2K
- Oct 2018Grant (prize money)$2.7M
#7
Seed · Nijmegen, Gelderland · founded 2022$2.4Mraised▾
AI-powered drug discovery platform for cancer treatment. The company utilizes a high-throughput proprietary approach for mapping cellular responses, combined with single-cell genomics and data science, we craft predictive models of disease biology and drug response.
- Apr 2025Seed$2.4M
#8
Series A · Nijmegen, Gelderland · founded 2011 · 13 employees$65Mraised▾
Developer of antibody-drug-conjugates for cancer treatment. It offers a lead product TGW101 that targets TAG72, a non-internalizing clinically validated pan-carcinoma target, present in several solid tumors. It also offersolid-tumor-targeted ADCs as well as radiopharmaceuticals including a HER2-targeted radioimmunotherapeutic.
- Jun 2023Series A$65M
- Mar 2023Grant (prize money)$477.5K
- Mar 2018Grant (prize money)$313.3K
- Jan 2016Grant (prize money)$1.7M
#9
Series C · Nijmegen, Gelderland · founded 2009 · 17 employees$82Mraised▾
Developer of toxin-loaded antibodies for T-cell mediated diseases. Based on the action of conjugated antibodies, it has developed its lead candidate T-Guard, a combination of two toxin-loaded anti-T-cell antibodies that can reset the body's immune system in T-cell mediated diseases, such as Graft-versus-host disease (GVHD).
- Oct 2022Grant (prize money)$2.5M
- Sep 2021Series C$47.4M
- May 2018Series B$30M
- Jun 2012Grant (prize money)$2.4M
#10
Series A · Nijmegen, Gelderland · founded 2017 · 10 employees$2.4Mraised▾
Manufacturer and developer of industrial robots. It supports communication and interaction for locked-in patients. The device is a headset that measures the electrical brain signals to control a computer for communicating using the brain-computer interface. The device doesn't need any training and can be controlled well with continuous use.
- Apr 2024Series A$1.2M
- Sep 2021Series A—
- Jul 2019Grant (prize money)$56.4K
- May 2018Seed$1.2M
#11
Deadpooled · Nijmegen, Gelderland · founded 2006 · 13 employees$32.9Mraised▾
Discovering and developing microRNA (miRNA)-based therapeutics for oncology. Developed a promising platform for the discovery and validation of miRNA-based drug candidates against previously undruggable targets in cancer. The product pipeline includes INT-5A2, INT-1B3 for the treatment of patients with liver cancer and skin cancer. It also developed various programs for pancreatic cancer, head and neck cancer, and bladder cancer.
- Feb 2021Series B$22.4M
- Jan 2021Grant (prize money)$325.7K
- Nov 2015Series A$10.5M
- Mar 2013Series A—
#12
Series A · Nijmegen, Gelderland · founded 2016 · 20 employees$11.9Mraised▾
Developer of smart diagnostics devices for blood coagulation analysis. It has developed the ENZYPAD devices that enable patient's blood coagulation analysis, with the measured data. It is a painless and easy to use blood sampling device that provides a test-specific single-use microfluidic cartridge includes all necessary reagents and controls. It uses proprietary innovative latent luciferin-protected peptide substrates to determine the activity of specific enzymes in the coagulation cascade. T
- Nov 2022Series A$11.9M
- Jul 2020Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Nijmegen researches in biotechnology
- Radboud University Nijmegen19
- Nijmegen Institute for Scientist Practitioners in Addiction1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.